Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Intelligent Health aim to get the whole community active by providing games and incentives such as ''beat the street''. By providing schools and communities with friendly competition to walk and cycle more by tapping their cards on ''beat boxes'', and with prizes and league tables on offer, Intelligent health are bringing communities together.
days to go:
Expired
investment:
£700,000
Smartlands is a blockchain-based digital finance and investment ecosystem. It allows asset owners to turn an ownership right to a share of any asset, into a tradable digital token attributing it almost unlimited liquidity. In the UK, Smartlands is the first platform for crowdfunding investments that allows investors to use digital currencies alongside fiat currencies to raise capital. The platform boasts of a 16,000 strong community following with over 11,000 wallets opened since its inception. It has a reputed list of partners including Colliers International, CMS, Archax, UK Sotheby’s, and many more. They have been awarded the 'Best Crowdfunding Platform' at the 2020 FinTech Breakthrough Awards and have been featured in Yahoo Finance, Forbes, Coindesk, Benzinga, and Investors Chronicle to name a few. With the investment, the company will grow its internal engineering team and obtain the necessary licenses to move its business forward across Europe.
days to go:
Expired
investment:
£379,183
Scribestar's Software-as-a-Service (SaaS) platform digitises and automates the documentation and compliance processes required for raising capital on stock markets such as IPOs, bonds etc. The platform intends to provide users with structured data format documents that can be machine-read and monetised. Scribestar aims to become a contender in the $22 billion Regulatory/Legal Technology markets. It argues that it is already active in the UK and has witnessed over 50 transactions on its system. It is also a part of the London Stock Exchange Issuer Services and CMS equIP with 4 years of verifiable commercial use and over £13 million received as investments. Scribestar asserts that its services are being regularly used by three law firms in the UK with more showing interest in its capability to function as a remote tool to manage the compliance documentation process. The company will use the investment to start its expansion in the US and other markets targeting law firms and deliver successful trials with stock exchanges.
days to go:
Expired
investment:
£864,009
Please watch the video for more information
days to go:
Expired
investment:
£376,618
Currently, the self-employed have fewer admissions to financial services than their employed counterparts do. Hatch aims to give sole traders free-to-use access to real-time credit scores that will allow lenders to make more informed decisions when invoice funding. The company also offers digitising of tax files, one of the most time-consuming admin burdens. Revenue is generated via affiliate fees to those who wish to introduce and facilitate Hatch on their platforms. A beta for 5k users will be launching soon, with half the slots already filled.
days to go:
Expired
investment:
£115,000
CoinBurp is a uniquely user-friendly crypto trading platform. It has a long-term vision to become an international brand and an integral part of the banking ecosystem. The company has acquired more than 1,000 users and facilitated 1000+ transactions, accumulating a trading volume of more than £1m. As CoinBurp enters its second phase of product development, it aims at providing banking facilities such as provide customers with prepaid cards, offer secured crypto loans and have initiated the process to become FCA regulated.
days to go:
Expired
investment:
£274,630
